AZmed – a leading European MedTech startup, has secured €15 million in Series A funding. The operation includes investors such as Maison Worms, Techstars, and Teampact Ventures. The investment supports AZmed’s overarching objective of shaping the future of medical imaging with artificial intelligence by accelerating radiologists’ workflows.
As part of a dynamic healthcare environment, doctors are progressively acknowledging the profound impact that artificial intelligence technologies can have. And AZmed plans to help overcome the obstacles doctors encounter when managing increasing workloads and providing timely, accurate diagnoses.
In 2019, AZmed’s AI software became the first ever to obtain CE marking for fracture detection on X-rays. And subsequently, it obtained FDA clearance in 2022 and has since been implemented in over 1,000 healthcare facilities across 40 countries.
The success of this software has led to partnerships with prominent healthcare institutions over the years, including the NHS, SimonMed Imaging, UH Cleveland Medical Center, and CHIREC. And it demonstrated remarkable effectiveness in detecting the main abnormalities shown on X-rays and significantly reducing the turnaround time for reports.
This funding round strategically positions AZmed to strengthen its leadership in Europe and extend its operations on a global scale, including in the US, the Middle East, Africa, and Asia. And within the next 18 months, the startup plans to double its workforce and substantially increase its investment in research and development to develop effective AI software further, thus expanding its line of medical imaging offerings.
KEY QUOTES:
“We are thrilled to have obtained this funding to advance AZmed to the forefront of the medical imaging industry. As the number of physicians has remained constant while the volume of medical images has increased, it is beyond dispute that each medical image must be correlated with a diagnosis of AI. Hence, AZmed is determined to pioneer the development of AI solutions in radiology to efficiently support the growing flow of images and improve the patient care pathway.”
- CEO of AZmed Julien Vidal
“The AZmed team has demonstrated unmatched commitment and creativity in tackling the pressing issues that affect healthcare practitioners. With this investment, AZmed will be in a strong position to enhance the care that is provided to patients. We share the company’s mission and are excited to be a part of its journey to transform healthcare.”
- Arnaud Decrulle from Maison Worms
